title: Emerging therapies for residual risk.
abstract: The role of statins in reducing the risk of coronary artery disease is well established.         The use of statins in patients at high risk for cardiovascular disease has reduced the         incidence of major clinical events by 25% to 40%. However, despite aggressive statin         therapy and the achievement of target low-density lipoprotein cholesterol levels, the         residual risk of cardiovascular events remains high. This review investigates emerging         therapies to target the residual risk of cardiovascular events with concurrent statin         therapy.
authors.affiliation: Department of Cardiovascular Sciences, East Carolina University Brody School of Medicine, Greenville, NC, USA.
authors.forename: Sanjay
authors.initials: S
authors.lastname: Mehra
authors.forename: Hossein
authors.initials: H
authors.lastname: Movahed
authors.forename: Assad
authors.initials: A
authors.lastname: Movahed
mesh_terms: D015415:Biomarkers / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D003324:Coronary Artery Disease / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D015507:Drugs, Investigational / Q000009:adverse effects / Q000627:therapeutic use*; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D050356:Lipid Metabolism / Q000187:drug effects; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D008078:Cholesterol, LDL; D015507:Drugs, Investigational; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors